Support worst-case product selection
Worst-case selection needs a scientific rationale and assessment of new products.
CV-REQ-000004
EU GMP Annex 15: Qualification and Validation§ 10.10
TOPIC EXPLORER
Shared Equipment
Connecting product characteristics, equipment and cross-contamination controls.
6 connected references
Reflect actual equipment use
Cleaning validation should reflect how equipment is actually used.
CV-REQ-000014
Q7A: Good Manufacturing Practice for APIs§ 12.7 — equipment usage
Establish and reassess HBELs
Establish HBELs for medicinal products and reassess supporting data periodically.
CV-REQ-000020
HBEL and cross-contamination: questions and answers§ Q1
Justify the changeover control strategy
Reduced analytical testing requires robust justification, including visual-inspection capability.
CV-REQ-000023
HBEL and cross-contamination: questions and answers§ Q7–Q8
Assess new products before introduction
Evaluate new products within the existing cleaning control strategy.
CV-REQ-000026
Cleaning validation guide (GUI-0028)§ 7.3.2
Use HBELs within risk assessment
HBEL implementation supports assessment of cross-contamination controls.
CV-REQ-000029
Cross-contamination control and HBEL Q&As§ Inspectorate commentary — HBEL implementation
Practical guidance
What FDA Has Been Citing in Cleaning Validation: The Recurring Themes of 2025–2026
Twelve FDA warning letters issued between 3 December 2024 and 24 July 2026 cite cleaning and cross-contamination control. Read together rather than case by case, they stop looking like twelve incidents and start looking like one audit checklist: worst-case selection, hold times, recovery, MACO justification, visual-only strategies, sampling locations, change control and lifecycle management — in that order of frequency.
ADCs Are Creating a New Cleaning Validation Problem
Antibody-drug conjugates combine a biologic, a chemical linker and a cytotoxic payload on shared equipment. A STERIS webinar frames the problem; independent guidance shows why one product-specific assay no longer answers the question.
Peptide APIs Put Cleaning Limits Under the Microscope: FDA Cites Missing MACO for Semaglutide and Tirzepatide
FDA's 1 May 2026 warning letter to Harbin Jixianglong Biotech found a cleaning procedure that required a toxicity-based carryover limit, and a validation study that established none — with no justification for swab locations and no swab results.
Worst Case or Product-Specific? New Research Reopens the Cleaning Validation Strategy Debate
A comparative review in the PDA Journal weighs worst-case matrices against product-specific validation and proposes a hybrid model anchored on visible residue limits.
Released as Clean, Yet Residue Remained: A Simple Finding With a Bigger System Lesson
An FDA investigator found white residue inside Tank #68 at Chemco Corporation — equipment the quality unit had already verified as clean. The finding itself is mundane. What it exposes about release decisions, shared equipment and the absence of cleaning validation is not.
EU and PIC/S Start the Next Revision of Annex 15 — What Validation Teams Should Watch
A joint EMA–PIC/S concept paper proposes extending Annex 15 to active substance manufacturers and aligning it with ICH Q9(R1). The current Annex 15 stays in force, and the earliest a revised text could be published is 2028.
Can a Cleaning Validation Demonstrate Reproducibility If Every Run Samples Somewhere Different?
FDA's Warning Letter 320-26-43 to Cosmetic Manufacturers (Aust) Pty Ltd. states that the firm's cleaning validation protocol 'was not designed to demonstrate reproducibility'. The cause is a design flaw that is easy to copy by accident: each qualification run sampled a different set of locations, so the runs were never replicates of the same measurement.
A Cleaning Verification Programme Is Only Useful If It Can Detect the Risk
FDA Warning Letter 320-26-40 to Cohance Lifesciences did not turn on a single residue number. It turned on whether the firm's verification programme could have found the carryover at all — and whether its worst-case basis was ever revisited.
When the Cleaning Validation No Longer Matches the Factory
FDA's December 2025 letter to Medinatura New Mexico records a firm acknowledging that its cleaning validation was not reflective of current operations after years of buying new equipment and adding new products. What the gap looks like from the inside — and what it asks of change control.
Cleaning Validation Is Becoming an Operational Strategy, Not Just a Compliance Exercise
A BeNeLux ISPE event on 23 September 2025 put 'business continuity' and 'culture' next to 'compliance' in the same talk title. That framing is the story: cleaning validation is being repositioned as an operational capability that keeps multi-product campaigns running, not a documentation obligation discharged before an inspection.
A Cleaning Validation Can Age: What Happens When Products Change but the Study Does Not
The FDA's August 2025 warning letter to ABBE Laboratories describes a 2009 cleaning validation still standing while a harder-to-clean product was introduced onto the same shared kettle — and no change-control step that caught it.
Should Cleaning Validation Extend Into the QC Laboratory?
A 2025 DARU Journal of Pharmaceutical Sciences study builds a structured cleaning-validation protocol for QC-lab glassware and stainless-steel equipment, using oxcarbazepine as worst-case API and pairing HPLC residue analysis with conductivity and TOC detergent checks.
What Does 'Clean' Mean When Equipment Status and Physical Condition Disagree?
A March 2025 FDA warning letter to Aspen Biopharma Labs Private Limited records investigators finding manufacturing equipment labelled "Cleaned" while liquid with a floating substance or residue remained on product-contact surfaces. That gap between a status tag and physical reality is one of the most consequential — and most preventable — failures in cleaning validation.
When MACO Is Not Enough: What the Granules India Warning Letter Really Teaches
The FDA rejected a retrospective MACO argument in a February 2025 warning letter — not because the arithmetic was wrong, but because the cleaning it assumed had not been performed. What cleaning-validation teams can take from it.
FDA Again Links Shared Equipment to the Need for a Lifecycle Cleaning Programme
A December 2024 warning letter to Brands International Corporation cites the firm under 21 CFR 211.67(b) for failing to perform cleaning validation studies on non-dedicated equipment — and asks for a cleaning programme built around worst-case products, worst-case swab sites and maximum hold times before cleaning.
When Shared Equipment Has Never Been Cleaning-Validated: Lessons From an FDA Warning Letter
An FDA Warning Letter to Indian API manufacturer Micro Orgo Chem describes non-dedicated equipment that had never been cleaned under a validated procedure, cleaning SOPs that were not followed, and no evidence that the rinse and swab samples required by the firm's own procedure were ever collected or tested.
What Happens to Biologics During Cleaning? New Data on Cleaning-Induced Protein Degradants
A bench-scale study puts the 650 ug/dose parenteral PDE for cleaning-induced protein degradants to the test with human-cell immunogenicity assays on HLE BiTE and mAb degradants, spiked into the same and a cross product.
Cleaning Validation Beyond Manufacturing Vessels: What About Blister Packaging?
A German hospital-pharmacy study argues blister-machine cleaning is a mandatory duty of care, and shows UV-Vis spectroscopy can replace HPLC as the analytical method.